STOCK TITAN

Insmed, Inc. - INSM STOCK NEWS

Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.

Insmed, Inc. (Symbol: INSM) is a global biopharmaceutical company headquartered in Bridgewater, NJ, with a mission to transform the lives of patients with serious and rare diseases. The company is committed to developing and bringing to market therapies that significantly improve patient lives, focusing on the entire patient journey from diagnosis and treatment to daily living.

Insmed's flagship product, ARIKAYCE (amikacin liposome inhalation suspension), is approved in the US for treating Mycobacterium Avium Complex (MAC) lung disease in adult patients who have limited or no alternative treatment options. ARIKAYCE, utilizing Insmed's proprietary PULMOVANCE® liposomal technology, delivers amikacin directly to the lungs, reducing systemic exposure and associated toxicities. It is administered using the Lamira® Nebulizer System developed by PARI Pharma GmbH, known for its efficiency and portability.

The company’s clinical pipeline includes multiple promising candidates. Notable among them is Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 (DPP1). It is being developed for treating non-cystic fibrosis bronchiectasis and other neutrophil-mediated diseases. Another significant pipeline product is TPIP (Treprostinil Palmitil Inhalation Powder), an inhaled formulation being evaluated for pulmonary arterial hypertension and other serious pulmonary disorders.

Insmed has demonstrated robust financial performance, with significant revenue growth driven by ARIKAYCE. The company continues to invest heavily in research and development, with plans to expand its product portfolio and market reach globally.

Insmed's strategic partnerships and collaborations play a crucial role in advancing its mission. These include collaborations with PARI Pharma for the Lamira® Nebulizer System and AstraZeneca AB for utilizing their expertise in respiratory diseases.

Recent updates include positive financial results for the third quarter of 2023, robust revenue growth from ARIKAYCE, and significant progress in clinical trials. Noteworthy are the topline results from the Phase 3 ASPEN study for Brensocatib, indicating its potential as a first-in-class treatment. Insmed plans to file a New Drug Application (NDA) with the FDA for Brensocatib by late 2024, aiming for a potential launch in 2025.

The company is also advancing its early-stage research engine, exploring innovative technologies such as artificial intelligence-driven protein engineering and gene therapy, positioning itself at the forefront of biopharmaceutical innovation.

Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM) announced that the European Commission has granted marketing authorization for ARIKAYCE® to treat nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium complex (MAC) in adults without cystic fibrosis. This approval follows the positive opinion from the EMA's Committee for Medicinal Products and is based on the Phase 3 CONVERT study, which showed ARIKAYCE improves sputum culture conversion rates. Insmed plans to launch ARIKAYCE in Germany and subsequently in other EU markets, supporting patients through tailored programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
none
-
Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM) announced the release of its third quarter 2020 financial results on October 29, 2020. A conference call for investors will take place at 8:30 a.m. ET to discuss these results. Interested participants can join by calling (833) 340-0284 domestically or (236) 712-2425 internationally and using conference ID number 8292364. A replay will be available two hours after the call until November 12, 2020. Insmed focuses on transforming lives through innovative therapies for rare diseases, including ARIKAYCE® for MAC lung disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.24%
Tags
conferences earnings
-
Rhea-AI Summary

Insmed has announced the granting of inducement awards to nine new employees as part of their recruitment strategy, compliant with NASDAQ Listing Rule 5635(c)(4). Each employee received options to purchase a total of 42,320 shares at an exercise price of $33.25, the closing price on October 1, 2020. The options come with a ten-year term and a four-year vesting schedule, designed to retain talent in a competitive industry. Insmed focuses on advancing therapies for serious and rare diseases, including ARIKAYCE, brensocatib, and treprostinil palmitil.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.76%
Tags
none
Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM) announced progress at its virtual R&D Day, highlighting its expanding portfolio aimed at treating serious and rare diseases. The company initiated a Phase 1 trial for Treprostinil Palmitil Inhalation Powder (TPIP) and plans to begin a Phase 2a study for pulmonary arterial hypertension in early 2021. Insmed aims to leverage its drug brensocatib to address neutrophil-mediated diseases, starting with a Phase 3 trial for non-cystic fibrosis bronchiectasis. The company also detailed global expansion efforts for its product ARIKAYCE, expecting EU marketing authorization by October 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
none
-
Rhea-AI Summary

Insmed, a biopharmaceutical company, will host a virtual R&D Day on September 30, 2020, from 10:00 a.m. to 12:30 p.m. ET. The event will highlight updates on pipeline candidates, including treprostinil palmitil and brensocatib, as well as advancements for ARIKAYCE (amikacin liposome inhalation suspension). Dr. Ronald J. Oudiz will present during the event. The conference call will be accessible live and recorded for later viewing. Insmed focuses on serious and rare diseases with its innovative therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.6%
Tags
conferences
-
Rhea-AI Summary

Insmed Incorporated (Nasdaq:INSM) announced participation in three virtual investor conferences in September 2020. Management will present at the H.C. Wainwright Annual Global Investment Conference on September 14, 2020, Morgan Stanley Annual Global Healthcare Conference on September 15, 2020, and the Cantor Virtual Healthcare Conference on September 17, 2020. Each presentation will be streamed live, accessible on the company's investor relations webpage and archived for 30 days. Insmed focuses on treatments for serious rare diseases, including its product ARIKAYCE®.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
conferences
Rhea-AI Summary

Insmed announced the publication of final results from the Phase 2 WILLOW study for brensocatib, a treatment for non-cystic fibrosis bronchiectasis (NCFBE), in the New England Journal of Medicine. Findings showed significant improvement in time to first pulmonary exacerbation compared to placebo, with risk reductions of 42% and 38% for two dosages. The treatment was well tolerated, with manageable adverse events. Insmed aims to initiate a Phase 3 program for brensocatib by year-end 2020, highlighting the urgency for therapeutic options in NCFBE.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM) announced the grant of inducement awards to 12 new employees as per NASDAQ Listing Rule 5635(c)(4). Approved by the Compensation Committee, these awards include options to purchase a total of 84,520 shares at an exercise price of $28.17 per share, which is the closing price on September 1, 2020. The options come with a ten-year term and a four-year vesting schedule, aimed at incentivizing employee retention and commitment to the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
none
-
Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM) has granted inducement awards to 11 new employees, in compliance with NASDAQ Listing Rule 5635(c)(4). These awards, approved by the Compensation Committee, consist of options to purchase a total of 76,960 shares of Insmed common stock at an exercise price of $27.15 per share, based on the closing price on August 3, 2020. The options are valid for a ten-year term and will vest over four years, promoting employee retention and commitment to the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
none
Rhea-AI Summary

Insmed reported strong Q2 2020 results, achieving $42.5 million in total revenue, up from $30.0 million in Q2 2019. U.S. sales of ARIKAYCE reached $41.0 million, reflecting growth amidst COVID-19 challenges. The company also reported a net loss of $61.9 million or $0.64 per share, improving from a $66.5 million loss in the prior year. Notably, brensocatib received FDA Breakthrough Therapy Designation, and ARIKAYCE gained a positive opinion from the CHMP for treating NTM lung infections, signaling potential market expansion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.19%
Tags

FAQ

What is the current stock price of Insmed (INSM)?

The current stock price of Insmed (INSM) is $70.59 as of December 23, 2024.

What is the market cap of Insmed (INSM)?

The market cap of Insmed (INSM) is approximately 12.5B.

What is Insmed's primary mission?

Insmed's mission is to transform the lives of patients with serious and rare diseases by developing and bringing to market innovative therapies.

What is ARIKAYCE?

ARIKAYCE (amikacin liposome inhalation suspension) is Insmed's first commercial product, approved for treating Mycobacterium Avium Complex (MAC) lung disease in adult patients with limited or no alternative treatment options.

What are Brensocatib and TPIP?

Brensocatib is an oral reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed for non-cystic fibrosis bronchiectasis and other inflammatory diseases. TPIP is an inhaled formulation of treprostinil for treating pulmonary arterial hypertension and other pulmonary disorders.

Where is Insmed headquartered?

Insmed is headquartered in Bridgewater, New Jersey, with additional offices and research locations worldwide.

What are Insmed's recent financial highlights?

Insmed reported significant revenue growth in the third quarter of 2023, particularly from ARIKAYCE sales, and continues to show strong financial performance.

What are the strategic partnerships of Insmed?

Insmed collaborates with PARI Pharma for the Lamira® Nebulizer System and AstraZeneca AB to leverage their expertise in respiratory diseases.

What are the latest developments in Insmed's clinical trials?

Recent highlights include positive topline results from the Phase 3 ASPEN study for Brensocatib, which showed significant treatment benefits, and ongoing evaluations of TPIP for various serious pulmonary conditions.

What is Insmed's approach to early-stage research?

Insmed is advancing an early-stage research engine encompassing innovative technologies, including artificial intelligence-driven protein engineering and gene therapy.

What is the Lamira® Nebulizer System?

The Lamira® Nebulizer System, developed by PARI Pharma, is a portable device used to administer ARIKAYCE efficiently through aerosolization.

When does Insmed plan to file an NDA for Brensocatib?

Insmed plans to file a New Drug Application (NDA) with the FDA for Brensocatib in the fourth quarter of 2024, with hopes for a U.S. launch in mid-2025.

Insmed, Inc.

Nasdaq:INSM

INSM Rankings

INSM Stock Data

12.54B
176.74M
0.91%
111.35%
6.76%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BRIDGEWATER